Press Releases

Issue of Shares for Exercised Warrants

By September 23, 2015No Comments

Motif (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announces that the Company has issued 140,321 new Ordinary Shares in settlement of an exercise of warrants.  The exercise price of the warrants was 20 pence.  The new Ordinary Shares represent 0.13% of the enlarged issued share capital.

Admission to trading on AIM of the 140,321 new Ordinary Shares, which rank parri passu with the existing Ordinary Shares, is expected on 28 September 2015. Following the allotment, the total issued share capital will increase to 108,486,537 Ordinary Shares with each share holding one voting right.

Enquiries

Motif Bio plc

Graham Lumsden, Chief Executive Officer
Robert Bertoldi, Chief Financial Officer
info@motifbio.com

MC Services AG (TRADE PR)

Raimund Gabriel
Shaun Brown
+49 (0) 89 210 2280
+44 (0) 207 148 5998

Zeus Capital Limited (Nominated Advisor and Broker)

Phil Walker / John Treacey
Dominic Wilson
+44 (0) 207 533 7727

Northland Capital Partners (Broker)

Patrick Claridge
John Howes
+44 (0) 207 382 1100

Plumtree Capital Limited (Financial Advisor)

Stephen Austin
+44 (0) 207 183 2493

Yellow Jersey PR

Dominic Barretto
Philip Ranger
Fiona Walker
+44 (0) 7768 537 739

Notes to Editors

Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.

Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.

The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.